Bionet

Bionet EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bionet (1784.TWO) as of Nov 2, 2026 is 280.62. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 62.24 — a change of 350.86% (higher).

EV/FCF

280.62

YoY

350.86%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bionet is 2025 280.62 . EV/FCF (Enterprise Value to Free Cash Flow) of Bionet was 2024 62.24 . It decreases by 350.86% higher compared to the previous year.

The Bionet EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-150.34 TWD
Jan 1, 2019
-499.60 TWD
Jan 1, 2020
114.31 TWD
Jan 1, 2021
-1,463.15 TWD
Jan 1, 2022
65.17 TWD
Jan 1, 2023
28.27 TWD
Jan 1, 2024
62.24 TWD
Jan 1, 2025
280.62 TWD
The Bionet EV/FCF history
YEAREV/FCFYoY
280.62+350.86%
62.24+120.16%
28.27-56.62%
65.17-104.45%
-1,463.15-1,379.96%
114.31-122.88%
-499.60+232.32%
-150.34+17.80%
-127.62+13.75%
-112.20-269.55%
66.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bionet is 280.62 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Bionet changed from 62.24 to 280.62, representing a 350.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bionet since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bionet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bionet

All Key Metrics — Bionet